The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable excitement within the sector. A shift away from Schedule I status, often viewed as outdated and hindering innovation, could unlock significant possibilities for ventures. Reduced regulatory restrictions, alongside greater access to banking and